

Supplementary Table 5. Combination of anti-diabetic drugs and change from baseline HbA1c in each group

Medication	Total subjects	Change from baseline HbA1c, %
SGLT2i only	18	-0.3
SGLT2i+Met	295	-0.5
SGLT2i+SU	8	-0.9
SGLT2i+DPP4i	1	-0.3
SGLT2i+TZD	1	-1.1
SGLT2i+Met+SU	225	-0.7
SGLT2i+Met+DPP4i	105	-0.7
SGLT2i+Met+TZD	14	-0.3
SGLT2i+SU+DPP4i	5	-1.0
SGLT2i+SU+TZD	3	-1.7
SGLT2i+DPP4i+TZD	1	-0.1
SGLT2i+Met+SU+DPP4i	95	-0.8
SGLT2i+Met+SU+TZD	25	-0.5
SGLT2i+Met+DPP4i+TZD	8	-1.1

HbA1c, glycosylated hemoglobin; SGLT2i, sodium-glucose co-transporter 2 inhibitor; Met, metformin; SU, sulfonylurea; DPP4i, dipeptidyl peptidase 4 inhibitor; TZD, thiazolidinedione.